<DOC>
	<DOCNO>NCT01227356</DOCNO>
	<brief_summary>Patients chronic myeloid leukemia imatinib induce CHR randomize imatinib 400 mg daily imatinib 400 mg daily + PegIntron 30 ug weekly . Primary endpoint : To compare 12 month treatment arm rate Major Molecular Response ( =99,9 % tumour reduction ) 12 month</brief_summary>
	<brief_title>A Study Comparing Imatinib Imatinib/Pegylated Interferon Chronic Myeloid Leukemia</brief_title>
	<detailed_description>130 patient register , 112 randomize . 56 pat treatment arm . 12 month study duration . Rate Major Molecular Response 12 month 53 vs 82 % ( p=0.002 ) favour combination arm .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Chronic myeloid leukemia imatinib induce complete hematological remission . Intermediate/low risk , ECOG &lt; 2 Les CHR 3 month imatinib high risk More 6 month diagnosis ECOG &gt; 2 Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Chronic myeloid leukemia , imatinib , interferon</keyword>
</DOC>